🇺🇸 FDA
Patent

US 10577381

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/5383A61K31/675

Quick answer

US patent 10577381 (Prodrugs of 2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/5383, A61K31/675, A61P, A61P1/04